Search research articles
Contact Us
Filters
Showing results (51-60 of 88) with videos related to
Page
of 9
Sort By:
Advances in Therapy
|
March 26, 2021
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
Anne J Paccaly, Michael R Migden, Kyriakos P Papadopoulos, et al.
Clinical and Translational Science
|
December 9, 2024
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer
Min Zhu, Priyanka Madia, Alison Crawford, et al.
Clinical and Translational Science
|
July 27, 2022
A drug-disease model for predicting survival in an Ebola outbreak
Masood Khaksar Toroghi, Nidal Al-Huniti, John D Davis, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 1, 2026
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, et al.
Journal of Clinical Pharmacology
|
August 8, 2013
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors
Yan Xin, Denise Jin, Stephen Eppler, et al.
The American Journal of Cardiology
|
February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583
Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology
|
March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical and Translational Science
|
January 8, 2022
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies
Min Zhu, Kara Olson, Jessica R Kirshner, et al.
Bioanalysis
|
November 8, 2021
REGEN-COV<sup>®</sup> antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification
Susan C Irvin, Samit Ganguly, Rachel Weiss, et al.
Frontiers in Immunology
|
March 26, 2026
The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccine
Susan C Irvin, Zhiqiang Wang, Samit Ganguly, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 88) with videos related to
Sort By:
Page
of 9
Advances in Therapy
|
March 26, 2021
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
Anne J Paccaly, Michael R Migden, Kyriakos P Papadopoulos, et al.
Clinical and Translational Science
|
December 9, 2024
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer
Min Zhu, Priyanka Madia, Alison Crawford, et al.
Clinical and Translational Science
|
July 27, 2022
A drug-disease model for predicting survival in an Ebola outbreak
Masood Khaksar Toroghi, Nidal Al-Huniti, John D Davis, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 1, 2026
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, et al.
Journal of Clinical Pharmacology
|
August 8, 2013
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors
Yan Xin, Denise Jin, Stephen Eppler, et al.
The American Journal of Cardiology
|
February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583
Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology
|
March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical and Translational Science
|
January 8, 2022
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies
Min Zhu, Kara Olson, Jessica R Kirshner, et al.
Bioanalysis
|
November 8, 2021
REGEN-COV<sup>®</sup> antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification
Susan C Irvin, Samit Ganguly, Rachel Weiss, et al.
Frontiers in Immunology
|
March 26, 2026
The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccine
Susan C Irvin, Zhiqiang Wang, Samit Ganguly, et al.
Page
of 9